nach oben

Archives of Gynecology and Obstetrics

Erschienen in:

20.11.2020 | Gynecologic Oncology

Association between BRCA mutations and endometrial carcinoma: a systematic review with meta-analysis

verfasst von: Guojiao Lu, Tao Lu, Jichen Pan, Ling Guo, Yingxin Pang, Peishu Liu

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 6/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To first investigate on the association between BRCA mutations and endometrial carcinoma. To first evaluate the contribution of tamoxifen use and risk-reducing bilateral salping-oophenrectomy (BSO) on endometrial carcinoma in BRCA carriers.

Methods

A systematic search of electronic databases including the PubMed and EMBASE was conducted to identify publications exploring the association between BRCA mutations and endometrial carcinoma. Finally, single rate meta-analysis and diagnostic meta-analysis were performed.

Results

11 retrospective studies and 3 prospective studies were included in the meta-analysis, single rate meta-analysis was performed on retrospective studies and prospective studies respectively. We got that incidence of BRCA mutations in patients with endometrial carcinoma is about 0.035, the incidence of endometrial carcinoma in BRCA carriers is about 0.004. Diagnostic meta-analysis performed on prospective studies found that tamoxifen increased incidence of endometrial carcinoma in BRCA carriers.

Conclusions

The incidence of BRCA mutations in patients with endometrial carcinoma is about 0.035 according to present studies, the incidence of endometrial carcinoma in BRCA carriers is about 0.004. Tamoxifen use is a certain risk factor for subsequent endometrial carcinoma, while history of breast cancer or risk-reducing BSO is not associated with incidence of follow-up endometrial carcinoma. The necessity and rationality of prophylactic hysterectomy for BRCA carriers remained to be discussed.

Benito V, Lubrano A, Arencibia O et al (2009) Pure papillary serous tumors of the endometrium: a clinicopathological analysis of 61 cases from a single institution. Int J Gynecol Cancer 19:1364–1369CrossRef

Miller KD, Goding Sauer A, Ortiz AP et al (2018) Cancer statistics for hispanics/latinos, 2018. CA Cancer J Clin 68:425–445CrossRef

Hornreich G, Beller U, Lavie O et al (1999) Is uterine serous papillary carcinoma a BRCA1-related disease? case report and review of the literature. Gynecol Oncol 75:300–304CrossRef

Bokhman JV (1983) Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15:10–17CrossRef

Samarnthai N, Hall K, Yeh IT (2010) Molecular profiling of endometrial malignancies. Obstet Gynecol Int 2010:162363CrossRef

Arend RC, Jones BA, Martinez A et al (2018) Endometrial cancer: Molecular markers and management of advanced stage disease. Gynecol Oncol 150:569–580CrossRef

Alobaid A, Bruchim I, Verkooijen H et al (2006) Adjuvant therapy for patients with stage I papillary serous endometrial cancer. Eur J Surg Oncol 32:358–362CrossRef

del Carmen MG, Birrer M, Schorge JO (2012) Uterine papillary serous cancer: a review of the literature. Gynecol Oncol 127:651–661CrossRef

Lax SF, Kurman RJ (1997) A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses. Verh Dtsch Ges Pathol 81:228–232PubMed

10.

Zhang Y, Garcia-Buitrago MT, Koru-Sengul T et al (2013) An immunohistochemical panel to distinguish ovarian from uterine serous papillary carcinomas. Int J Gynecol Pathol 32:476–481CrossRef

11.

Usach I, Blansit K, Chen LM et al (2015) Survival differences in women with serous tubal, ovarian, peritoneal, and uterine carcinomas. Am J Obstet Gynecol 212(188):e1-6

12.

Moynahan ME, Chiu JW, Koller BH et al (1999) Brca1 controls homology-directed DNA repair. Mol Cell 4:511–518CrossRef

13.

Orban TI, Olah E (2003) Emerging roles of BRCA1 alternative splicing. Mol Pathol 56:191–197CrossRef

14.

Beiner ME, Finch A, Rosen B et al (2007) The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. Gynecol Oncol 104:7–10CrossRef

15.

Segev Y, Iqbal J, Lubinski J et al (2013) The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study. Gynecol Oncol 130:127–131CrossRef

16.

Shu CA, Pike MC, Jotwani AR et al (2016) Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations. JAMA Oncol 2:1434–1440CrossRef

17.

Signorelli M, Bogani G, Ditto A et al (2016) Risk-reducing surgery on the uterine adnexa: timing and type of surgical treatment, and pathology report. Minerva Ginecol 68:536–543PubMed

18.

Kauff ND, Domchek SM, Friebel TM et al (2008) Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 26:1331–1337CrossRef

19.

Garabedian C, Lejeune S, Merlot B et al (2013) Indications for prophylactic hysterectomy. Gynecol Obstet Fertil 41:620–623CrossRef

20.

Niederacher D, An HX, Camrath S et al (1998) Loss of heterozygosity of BRCA1, TP53 and TCRD markers analysed in sporadic endometrial cancer. Eur J Cancer 34:1770–1776CrossRef

21.

Goshen R, Chu W, Elit L et al (2000) Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome? Gynecol Oncol 79:477–481CrossRef

22.

Levine DA, Lin O, Barakat RR et al (2001) Risk of endometrial carcinoma associated with BRCA mutation. Gynecol Oncol 80:395–398CrossRef

23.

Lavie O, Hornreich G, Ben-Arie A et al (2004) BRCA germline mutations in Jewish women with uterine serous papillary carcinoma. Gynecol Oncol 92:521–524CrossRef

24.

Biron-Shental T, Drucker L, Altaras M et al (2006) High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma. Eur J Surg Oncol 32:1097–1100CrossRef

25.

Lavie O, Ben-Arie A, Segev Y et al (2010) BRCA germline mutations in women with uterine serous carcinoma–still a debate. Int J Gynecol Cancer 20:1531–1534PubMed

26.

Bruchim I, Amichay K, Kidron D et al (2010) BRCA1/2 germline mutations in Jewish patients with uterine serous carcinoma. Int J Gynecol Cancer 20:1148–1153CrossRef

27.

Barak F, Milgrom R, Laitman Y et al (2010) The rate of the predominant Jewish mutations in the BRCA1, BRCA2, MSH2 and MSH6 genes in unselected Jewish endometrial cancer patients. Gynecol Oncol 119:511–515CrossRef

28.

Pennington KP, Walsh T, Lee M et al (2013) BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma. Cancer 119:332–338CrossRef

29.

Mahdi H, Xiu J, Reddy SK et al (2015) Alteration in PI3K/mTOR, MAPK pathways and Her2 expression/amplification is more frequent in uterine serous carcinoma than ovarian serous carcinoma. J Surg Oncol 112:188–194CrossRef

30.

Kadan Y, Raviv O, Segev Y et al (2018) Impact of BRCA mutations on outcomes among patients with serous endometrial cancer. Int J Gynaecol Obstet 142:91–96CrossRef

31.

Reitsma W, Mourits MJ, de Bock GH et al (2013) Endometrium is not the primary site of origin of pelvic high-grade serous carcinoma in BRCA1 or BRCA2 mutation carriers. Mod Pathol 26:572–578CrossRef

32.

Metcalfe KA, Snyder C, Seidel J et al (2005) The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation. Fam Cancer 4:97–103CrossRef

33.

Yerushalmi R, Rizel S, Zoref D et al (2016) A dedicated follow-up clinic for BRCA mutation carriers. Isr Med Assoc J 18:549–552PubMed

34.

Ricciardi E, Tomao F, Aletti G et al (2017) Risk-reducing salpingo-oophorectomy in women at higher risk of ovarian and breast cancer: a single institution prospective series. Anticancer Res 37:5241–5248PubMed

35.

Saule C, Mouret-Fourme E, Briaux A et al (2018) Risk of Serous Endometrial Carcinoma in Women With Pathogenic BRCA1/2 Variant After Risk-Reducing Salpingo-Oophorectomy. J Natl Cancer Inst 110:213CrossRef

36.

Struewing JP, Hartge P, Wacholder S et al (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401–1408CrossRef

37.

Easton DF, Steele L, Fields P et al (1997) Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am J Hum Genet 61:120–128CrossRef

38.

Goggins M, Schutte M, Lu J et al (1996) Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 56:5360–5364PubMed

39.

Meyer LA, Broaddus RR, Lu KH (2009) Endometrial cancer and Lynch syndrome: clinical and pathologic considerations. Cancer Control 16:14–22CrossRef

40.

Zhong Q, Peng HL, Zhao X et al (2015) Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis. Clin Cancer Res 21:211–220CrossRef

Titel: Association between BRCA mutations and endometrial carcinoma: a systematic review with meta-analysis
verfasst von: Guojiao Lu
Tao Lu
Jichen Pan
Ling Guo
Yingxin Pang
Peishu Liu
Publikationsdatum: 20.11.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Archives of Gynecology and Obstetrics / Ausgabe 6/2021
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-020-05887-7

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Menopausale Hormontherapie für Frauen über 65?

07.05.2024 Klimakterium und Menopause Nachrichten

In den USA erhalten nicht wenige Frauen auch noch im Alter über 65 eine menopausale Hormontherapie. Welche positiven und negativen gesundheitlichen Konsequenzen daraus möglicherweise resultieren, wurde anhand von Versicherungsdaten analysiert.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Bildnachweise

Digitale Mammographien links in kraniokaudaler Projektion./© Weigel, S. et al. / all rights reserved Springer Medizin Verlag GmbH, Frau klebt Pflaster auf den Oberschenkel/© svetikd / Getty Images / iStock (Symbolbild mit Fotomodell), Medizinische Fachangestellte sitzt erschöpft auf der Treppe/© Courtney Haas / peopleimages.com /stock.adobe.com (Symbolbild mit Fotomodell), Junge Frau untersucht Gewebeprobe/© luchschenF / Stock.adobe.com (Symbolbild mit Fotomodell)

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2021

TP53 germline mutations in the context of families with hereditary breast and ovarian cancer: a clinical challenge

Clinical features of ProMisE groups identify different phenotypes of patients with endometrial cancer

Transferability of the early-stage ovarian malignancy (EOM) score: an external validation study that includes advanced-stage and metastatic ovarian cancer

Predicting postpartum post-traumatic stress and depressive symptoms in low-risk women from distal and proximal factors: a biopsychosocial prospective study using structural equation modeling